Results 41 to 50 of about 48,363 (248)

Evolution of a subtilisin-like protease gene family in the grass endophytic fungus Epichloë festucae

BMC Evolutionary Biology, 2009
Background Subtilisin-like proteases (SLPs) form a superfamily of enzymes that act to degrade protein substrates. In fungi, SLPs can play either a general nutritive role, or may play specific roles in cell metabolism, or as pathogenicity or virulence ...
Hesse Uljana, Schardl Christopher L, Bryant Michelle K, Scott Barry   +3 more
doaj   +1 more source

Clinical exome performance for reporting secondary genetic findings. [PDF]

, 2014
BACKGROUND : Reporting clinically actionable incidental genetic findings in the course of clinical exome testing is recommended by the American College of Medical Genet- ics and Genomics (ACMG).
Clark, P, Fortina, Paolo, Kricka, Lj, Londin, E, Park, J. Y., Park, Jy, Sponziello, Marialuisa   +6 more
core   +1 more source

Developmental sensory experience balances cortical excitation and inhibition. [PDF]

, 2010
Early in life, neural circuits are highly susceptible to outside influences. The organization of the primary auditory cortex (A1) in particular is governed by acoustic experience during the critical period, an epoch near the beginning of postnatal ...
Barker, Alison J, Dorrn, Anja L, Froemke, Robert C, Schreiner, Christoph E, Yuan, Kexin   +4 more
core   +3 more sources

Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor

JACC: Case Reports, 2020
A 72-year-old man with coronary artery disease, statin intolerance, and chronic kidney disease stage IIIa was initiated on alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, and developed acute kidney injury.
June K. Pickett, MD, Maulin Shah, MD, Michael Gillette, PharmD, Peter Jones, MD, Salim Virani, MD, PhD, Christie Ballantyne, MD, Vijay Nambi, MD, PhD   +6 more
doaj   +1 more source

Proprotein Convertase Subtilisin/Kexin 6 in Cardiovascular Biology and Disease

International Journal of Molecular Sciences, 2022
Proprotein convertase subtilisin/kexin 6 (PCSK6) is a secreted serine protease expressed in most major organs, where it cleaves a wide range of growth factors, signaling molecules, peptide hormones, proteolytic enzymes, and adhesion proteins. Studies in Pcsk6-deficient mice have demonstrated the importance of Pcsk6 in embryonic development, body axis ...
Qingyu Wu, Shenghan Chen
openaire   +2 more sources

Non-Destructive Thickness Measurement of Energy Storage Electrodes via Terahertz Technology

Sensors
Precision thickness control in new energy electrode coatings is a critical determinant of battery performance characteristics. This study presents a non-destructive inspection methodology employing terahertz time-domain spectroscopy (THz-TDS) to achieve ...
Zhengxian Gao, Xiaoqing Jia, Jin Wang, Zhijun Zhou, Jianyong Wang, Dongshan Wei, Xuecou Tu, Lin Kang, Jian Chen, Dengzhi Chen, Peiheng Wu   +10 more
doaj   +1 more source

PCSK9 induces a pro-inflammatory response in macrophages [PDF]

, 2018
Intraplaque release of inflammatory cytokines from macrophages is implicated in atherogenesis by inducing the proliferation and migration of media smooth muscle cells (SMCs). PCSK9 is present and released by SMCs within the atherosclerotic plaque but its
Adorni, Maria Pia, Camera, Marina, Cicero, Arrigo F G, Colciago, Alessandra, Corsini, Alberto, Ferri, Nicola, Fogacci, Federica, LUPO, MARIA GIOVANNA, Macchi, Chiara, Ricci, Chiara, Rossetti, Laura, Ruscica, Massimiliano, Zanotti, Ilaria   +12 more
core   +3 more sources

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview [PDF]

The American Journal of Medicine, 2017
Proprotein convertase subtilisin/kexin type 9 inhibitors serve as a valuable addition to the armamentarium of lipid-lowering agents and have promising potential. By inhibiting the proprotein convertase subtilisin/kexin type 9 enzyme, this novel molecule leads to increased low-density lipoprotein receptor density and decreased circulation of low-density
Zachary R, Noel, Craig J, Beavers
openaire   +2 more sources

A cost-effectiveness analysis of the combination of serplulimab with chemotherapy for advanced esophageal squamous cell carcinoma: insights from the ASTRUM-007 trial

Cost Effectiveness and Resource Allocation
Background Combined serplulimab and chemotherapy demonstrated improved clinical survival outcomes in patients with advanced esophageal squamous cell carcinoma (ESCC) and PD-L1 combined positive scores (CPS) ≥ 1.
Jiahui Li, Chaoqun Xu, Suyun Yuan
doaj   +1 more source

Development of a Prediction Model for Progression Risk in High‐Grade Gliomas Based on Habitat Radiomics and Pathomics

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate the value of constructing models based on habitat radiomics and pathomics for predicting the risk of progression in high‐grade gliomas. Methods This study conducted a retrospective analysis of preoperative magnetic resonance (MR) images and pathological sections from 72 patients diagnosed with high‐grade gliomas (52 ...
Yuchen Zhu, Yuxi Gong, Weilin Xu, Xingjian Sun, Gefei Jiang, Lei Qiu, Kexin Shi, Mengxing Wu, Yinjiao Fei, Jinling Yuan, Jinyan Luo, Yurong Li, Yuandong Cao, Minhong Pan, Shu Zhou   +14 more
wiley   +1 more source